



UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2018 P 3082-3
Program	Step Therapy
Medication	Tasigna [®] (nilotinib)
P&T Approval Date	10/2016, 10/2017, 10/2018
Effective Date	2/1/2019; Oxford only: 2/1/2019

1. Background:

Step Therapy programs are utilized to encourage the use of lower cost alternatives for certain therapeutic classes. This program requires a patient trial or physician consideration of imatinib before providing coverage for Tasigna in the setting of Philadelphia chromosome-positive chronic myelogenous/myeloid leukemia.

Coverage Information:

Members will be required to meet the criteria below for coverage. For members under the age of 19 years, the prescription will automatically process without a coverage review. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances. Some states also mandate usage of other Compendium references. Where such mandates apply, they supersede language in the benefit document or in the notification criteria.

2. Coverage Criteria ^a:

A. Patients less than 19 years of age

1. **Tasigna** will be approved based on the following criterion:

- a. Patient is less than 19 years of age

Authorization will be issued for 12 months.

B. Philadelphia Chromosome-Positive Chronic Myelogenous / Myeloid Leukemia (Ph+ CML)

1. **Tasigna** will be approved based on **both** of the following criterion:

- a. Diagnosis of Philadelphia chromosome-positive chronic myelogenous / myeloid leukemia (Ph+ CML)

-AND-

- b. **One** of the following:

(1) Patient is not a suitable candidate for imatinib as attested by physician

-OR-

(2) As continuation of therapy

Authorization will be issued for 12 months

C. Other Indications

1. Tasigna will be approved

Authorization will be issued for 12 months

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply

3. Additional Clinical Rules:

- Supply limits and/or Notification may be in place.

4. References:

1. Tasigna [package insert]. East Hanover, NJ: Novartis; July 2018.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed September 5, 2018.

Program	Step Therapy - Tasigna (nilotinib)
Change Control	
10/2016	New program.
10/2017	Annual review. Updated state mandate verbiage. Updated references.
10/2018	Annual review with no changes to coverage criteria. Updated references.